2
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
246
Precursor Cell Lymphoblastic Leukemia-Lymphoma
147
Myelodysplastic Syndromes
144
Leukemia, Lymphocytic, Chronic, B-Cell
140
Leukemia
128
Multiple Myeloma
118
Lymphoma
116
Lymphoma, Non-Hodgkin
112
Recurrence
80
Hematologic Neoplasms
77
Melanoma
68
Hodgkin Disease
68
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
67
Lymphoma, B-Cell
61
Lymphoma, Mantle-Cell
52
Lymphoma, Large B-Cell, Diffuse
50
Lymphoma, Follicular
50
Burkitt Lymphoma
41
Ovarian Neoplasms
40
Neoplasms
39
Myeloproliferative Disorders
39
Neoplasm Metastasis
34
Lymphoma, B-Cell, Marginal Zone
30
Graft vs Host Disease
29
Neoplasms, Plasma Cell
28
Carcinoma, Non-Small-Cell Lung
27
Breast Neoplasms
27
Leukemia, Biphenotypic, Acute
25
Primary Myelofibrosis
24
Anemia, Refractory, with Excess of Blasts
23
Interventions
Rituximab
10
Valganciclovir
6
Etoposide
4
Doxorubicin
4
Valacyclovir
3
Gemcitabine
3
Dexamethasone
3
Cyclophosphamide
3
Cisplatin
3
spartalizumab
2
pembrolizumab
2
pegaspargase
2
Zidovudine
2
Vincristine
2
Radiotherapy, Intensity-Modulated
2
Prednisone
2
Methylprednisolone
2
Methotrexate
2
Matrix-M
2
Leucovorin
2
Lenalidomide
2
Cell Count
2
Carboplatin
2
Blood Specimen Collection
2
Acyclovir
2
valomaciclovir
1
toripalimab
1
threonic acid
1
ruxolitinib
1
pomalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Epstein-Barr Virus Infections
×
fludarabine
×
Clear all
NCT06224049
2024-03-12
GI-hNeoT-01
BGI, China
Phase EARLY_PHASE1
Recruiting
6 enrolled